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EXPERT REVIEWRegression of ‘‘fixed’’ pulmonary vascular resistance in heart
transplant candidates after unloading with ventricular assist devicesFriedhelm Beyersdorf, MD, PhD, Christian Schlensak, MD, PhD, Michael Berchtold-Herz, MD, and
Georg Trummer, MDPulmonary hypertension is a risk factor for early and late
mortality after heart transplantation. An increase in pulmo-
nary artery pressure secondary to long-standing elevations
in left atrial pressures is observed in 33% to 72% of all pa-
tients with end-stage heart failure. This increase is dispro-
portionate to the increase in left atrial pressure, thus
causing an increased transpulmonary gradient and an in-
creased pulmonary vascular resistance (pulmonary vascular
resistance [Wood units] ¼ transpulmonary gradient/cardiac
output) over time. All patients with increased pulmonary
vascular resistance greater than 3 Wood units or transpulmo-
nary gradients greater than 10 mm Hg are subjected to a stan-
dardized protocol testing the reversibility of the elevated
pulmonary artery pressure by pharmacologic interventions
before cardiac transplantation. Pulmonary vascular resis-
tance that cannot be lowered pharmacologically is termed
‘‘fixed’’ pulmonary vascular resistance. It has been shown
that ventricular assist devices are able to reduce pulmonary
vascular resistance even in patients who are unresponsive
to pharmacologic reduction of pulmonary vascular resis-
tance, thus allowing a listing for transplantation after a rela-
tively short period of mechanical support (ie, 3–6 months).SIGNIFICANCE OF PULMONARY
HYPERTENSION IN PATIENTS WITH END-STAGE
HEART FAILURE
Pulmonary hypertension (PHT) is a risk factor for early
and late mortality after heart transplantation (HTX) with
mortality rates up to 40%.1,2 Moreover, Erickson and
associates2 stated that right ventricular dysfunction accounts
for approximately 50% of all cardiac complications and
20% of early mortality after HTX.
In the initial phase of heart failure, increases in pulmonary
artery pressure (PAP) occur in proportion to an increase of
left atrial pressures that can be determined indirectly by mea-
suring the pulmonary capillary wedge pressure (PCWP).
Therefore, in this early stage with initially normal pulmo-
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The Journal of Thoracic and Cagradient (TPG) exists (TPG ¼ mean PAPPCWP).3 Often
PVR is also described in Wood units (WU ¼ TPG/cardiac
output).
However, long-standing elevations in left atrial pressures
result in an increase in PAP in about 33% to 72% of all pa-
tients with end-stage heart failure.3,4 This increase in PAP is
disproportionate to the increase in left atrial pressure
(PCWP), thus causing an increased TPG and an increased
PVR over time. It may be speculated that the increased
incidence of patients with higher PVR evaluated for HTX
may be related to the fact that patients can be supported
longer with modern medical treatment until they finally
need to be listed for HTX.
According to the severity of PHT, 3 groups have been
defined: no PHT (PVR<3 WU, TPG<10 mm Hg); mild-
to-moderate PHT (PVR 3–6 WU, TPG 10–20 mm Hg);
and severe PHT (PVR>6 WU, TPG>20 mm Hg).
All patients with increased PVR greater than 3 WU or
TPG greater than 10 mm Hg are subjected to a standardized
protocol testing the reversibility of the elevated PAP by
pharmacologic interventions before HTX (Table 1). Phar-
macologic agents tested include oxygen, nitroglycerin, so-
dium nitroprusside, inhaled nitric oxide, phosphodiesterase
inhibitors, urapidil, prostaglandins E1 and I1, and sildenafil.PHT AND HTX
Mortality after HTX is increased if pharmacologic
interventions are not able to reduce PVR below certain levels.
This threshold is reported to be between 2.5 and 3.5 WU or
more.5,6 A PVR that cannot be reduced by pharmacologic
interventions below either 2.5 or 3.5 WU is usually termed
‘‘fixed’’ PVR. The pathophysiology of ‘‘fixed’’ PHT is
multifactorial and seems to include vascular remodeling at
the capillary level, in situ thrombosis, and vasoconstriction.7
The International Society of Heart and Lung Transplanta-
tion Guidelines and the Canadian Cardiovascular Society
Consensus Conference on Cardiac Transplantation suggest
that PAP greater than 50 mm Hg systolic, PVR greater
than 4 to 5 WU, and a TPG greater than 15 to 16 mm Hg
are at least relative, if not absolute, contraindications to car-
diac transplantation.8,9 However up to date, there is no
reliable hemodynamic threshold known beyond which
right ventricular failure after transplant is certain to occur,
nor are there values below which right ventricular failure
is always avoidable.10 Even if PVR can be reduced to less
than 2.5 WU by using a vasodilator and systolic bloodrdiovascular Surgery c Volume 140, Number 4 747
TABLE 1. Pharmacologic testing for reversal of pulmonary vascular
resistance before listing for heart transplantation: Freiburg protocol
1. Determination of baseline hemodynamics
2. Application of oxygen Lifeline mask 5 L/min
3. Application of nitrates 30-100 mg/min
4. Application of inhalative iloprost 2.5-5 mg
5. Application of dobutamine 2-6 mg/kg/min
6. Application of inhalative nitric oxide 40 ppm or oral application
of sildenafil 25 mg
Expert Review Beyersdorf et alpressure is less than 85 mm Hg, the patient remains at high
risk for right heart failure.8
We have evaluated our own recent 140 HTX patients and
found in 29% (40/140 patients) a PVR greater than 2.5 WU
and in 5% (7/140) a PVR greater than 3.5 WU despite
pharmacologic interventions (Table 1). A similar percentage
of patients with fixed PVR (18%) was reported by others.6
In one third of patients in another series, elevated PAP
was refractory to medical treatment.11
Previous treatment options for patients with end-stage
heart failure and fixed PVR were heterotopic HTX, combined
heart-lung transplantation, and right ventricle–sparing trans-
plantation.4 Inasmuch as the results of these alternative treat-
ment options were clearly inferior to orthotopic HTX, most of
these patients received no transplantation at all. Transplanta-
tion using hearts from donors with primary PHT for recipients
with a high PVR (domino procedure) is another viable but
rare option in transplant centers where patients undergo heart
and lung transplantation for primary PHT.12
THERAPY WITH A VENTRICULAR ASSIST
DEVICE CAN REVERSE ‘‘FIXED’’ PHT
As an alternative, reports and case studies have been pub-
lished showing that pulsatile ventricular assist devices
(VADs) reduce PHT in patients with end-stage heart failure.
In 1991 Gallagher and colleagues13 demonstrated in 16
patients that mechanical support with a Novacor device
(Novacor, Inc, Rueil-Malmaison, France) resulted in
reduced PHT. This observation was confirmed by other
authors in the following years.14-16
In the year 2000 we have started to implant left ventricular
assist devices (LVAD) in patients with fixed PVR for desti-
nation therapy. A significant reduction in PVR was observedFIGURE 1. Long-term survival after heart transplantation in patients with and w
tricular assist device.
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Eventually, the patients could be listed for HTX and under-
went successful transplantation. After fixed PVR was suc-
cessfully reversed with pulsatile and nonpulsatile VADs in
the first 6 patients, this experience was published as a prelim-
inary report in 2004.17 The reduction in PVR occurred even
in patients with markedly elevated PVR (>7 WU).17 Impor-
tantly, PHT did not return after HTX in our patients.
This observation that unloading of the left ventricle by
pulsatile and nonpulsatile VADs is able to reverse previously
‘‘fixed’’ PVR was subsequently confirmed by other
groups.3,6,18-21 Survival of these patients after transplantation
was comparable with that of patients without prior PHT.22
Reversal of fixed PVR occurs after a short period (weeks
to months) of mechanical circulatory support. Salzberg and
coworkers21 reported this decrease to occur after 6 weeks of
LVAD support. This is confirmed by Etz and colleagues3 for
the majority of their patients after implantation of nonpulsa-
tile LVADs; after 6 months all their patients had PVR less
than 3 WU. Zimpfer and associates6 also reported that the
decrease in PVR occurred within a 6-week follow-up period.
Normalization of PVR after lowering the pressures in the
left-sided heart chambers is not a recent observation in VADithout prior mechanical circulatory support: Freiburg experience.VAD,Ven-
ery c October 2010
Beyersdorf et al Expert Reviewpatients with congestive heart failure. There are also reports
showing the same regression of PVR after successful ortho-
topic HTX in patients with elevated (reversible) PVR before
HTX (normalization of PVR at 1 year after HTX).11 In addi-
tion, it has been known for decades that high PVR owing to
severe mitral stenosis can also be reversed if pressures in the
left atrium are decreased by mitral valve surgery.23
The pathophysiology of PHT in patients with terminal
heart failure is a multifactorial process not finally elucidated,
but mainly related to left ventricular failure.24 The mecha-
nisms by which unloading of the left ventricle and atria
(eg, by VAD) result in reversal of ‘‘fixed’’ PVR are un-
known at present. One mechanism might be that relieved
pulmonary congestion and normalized pulmonary hemody-
namics reduce overproduction of intrinsic vasoconstrictors,
which has been triggered by shear stress previously.3
Our own experience with mechanical circulatory support
before HTX shows that the posttransplant survival is at least
as good as (if not better than) that of patients receiving HTX
without prior VAD support (Figure 1). These excellent long-
term HTX results in patients with prior LVAD therapy as
compared with those without prior LVAD support have
also been reported by others.5
The major disadvantage of mechanical circulatory sup-
port is still the morbidity and mortality rate. However, recent
publications have shown a significant improvement in the
results after long-term mechanical support with 6- and
12-month survivals of 80% and 70%, respectively.25CONCLUSIONS
In conclusion, ‘‘fixed’’ PHT in patients with terminal
heart failure can be reversed by temporary VAD support.
This reduction in PVR occurs by 6 to 12 weeks in most pa-
tients, even in those with markedly elevated PVR (>7 WU).
Long-term post-HTX outcome after reversal of ‘‘fixed’’
PHT with VADs is as good as (or even better than) that of
HTX in patients without fixed PVR. However, VAD compli-
cations (morbidity and mortality) also have to be considered
if this kind of treatment is chosen.References
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